All Cancer articles
-
NewsCircio and Acuitas partner on circular RNA CAR T therapy
Norway-based biotechnology company Circio Holding ASA has partnered with Acuitas Therapeutics to evaluate its circVec circular RNA platform for in vivo CAR T cell therapy. The collaboration will combine Circio’s technology, which reportedly delivers gene expression lasting up to six months in lymphocytes, with Acuitas’ lipid nanoparticle delivery system targeting specific T cell populations for potential applications in oncology and autoimmune diseases.
-
NewsChampions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
-
NewsMassey Cancer Center funds drug discovery projects targeting Hsp27-CerS1 and ferroptosis pathways
The VCU Massey Comprehensive Cancer Center has awarded $50,000 each to two innovative drug discovery projects through its collaborative programme with Sanford Burnham Prebys Medical Discovery Institute.
-
NewsLactylation emerges as key driver of lung cancer resistance
New research from Shanghai Pulmonary Hospital outlines how lactate-driven lactylation acts as a metabolic switch controlling epigenetic regulation in lung cancer. The findings reveal self-reinforcing feedback loops that sustain drug resistance and suggest novel therapeutic strategies targeting the enzymes and pathways that maintain this process.
-
News3D-printed drug carriers deliver chemotherapy directly to tumours
Novel FRESH 3D printing technology enables fabrication of nanoscale spanlastic carriers for localised anticancer drug delivery. Early in vitro studies have demonstrated enhanced cellular uptake and tumour cell killing whilst potentially minimising systemic toxicity associated with conventional chemotherapy administration.
-
NewsDNA-based system delivers targeted cancer drugs via biomarker logic
Researchers at the University of Geneva have developed a DNA-based drug delivery platform that uses molecular logic gates to identify cancer cells through dual biomarker recognition. The system activates cytotoxic agents only when both tumour markers are present, offering enhanced specificity over current antibody–drug conjugates while enabling deeper tissue penetration and multi-drug combinations.
-
ArticleAnticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
-
ArticleKMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as highly selective immunotherapy targets across plasma cell dyscrasias.
-
NewsCOPD drug roflumilast may help fight breast cancer lung metastasis
University of Colorado Anschutz Cancer Center scientists have uncovered how metastatic breast cancer cells exploit pulmonary repair pathways to establish tumours in the lungs.
-
NewsNew AI-designed T-cell engager LGTX-101 to be presented at AACR in San Diego
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
-
NewsProbiotic bacteria successfully attacks tumours in preclinical models
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
-
NewsSonoPIN ultrasound method shows promise for targeted cancer therapy
A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.
-
NewsNew drug delivery system boosts paclitaxel cancer treatment
Researchers at Osaka Metropolitan University have developed a novel drug delivery system that improves the solubility of the anticancer drug paclitaxel.
-
NewsScientists develop cream that triggers skin’s anti-cancer defence
A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.
-
NewsSimple amino acid mix dramatically improves gene therapy delivery
Scientists have discovered that adding a simple cocktail of three common amino acids to lipid nanoparticle injections can dramatically improve the delivery of mRNA and CRISPR therapies.
-
NewsDeep-sea compound yaku’amide B shows new cancer-fighting mechanism
Japanese researchers have discovered how yaku’amide B, a rare compound from deep-sea sponges, targets aggressive cancer cells.
-
NewsNew target found for glaucoma treatment
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
-
ArticleWorld ADC 2026: where antibody-drug conjugates are heading
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
-
NewsBlocking FAK protein may help to overcome resistance in ovarian cancer
A new preclinical study has demonstrated that locking the focal adhesion kinase (FAK) protein may help the immune system better detect and attack ovarian tumours.
-
ArticlePreclinical takeaways from the World ADC Conference London
Experts from the World ADC Conference in London highlight how patient-centric, predictive preclinical tools and innovative ADC designs are improving safety, efficacy and clinical translation.